Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
Want to see HK:2185 full AI Analyst Report?
Top Page
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
(2185)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$2.50
▼(-56.22% Downside)
Action:Reiterated
Date:05/28/26
The score is weighed down primarily by weak financial performance—persistent operating losses and continued cash burn—despite some revenue rebound and a low-debt balance sheet. Technicals add further pressure with a strong downtrend and negative momentum, while valuation remains hard to justify given negative earnings and no dividend support.
Positive Factors
Low leverage / solid solvency
A very low debt load provides durable financial flexibility: it reduces near-term default and interest burden, supports the ability to raise growth capital on better terms, and gives time to execute R&D and commercialization plans without immediate solvency pressure.
Negative Factors
Persistent operating losses
Sustained operating losses erode equity and limit reinvestment capacity. Over 2-6 months this constrains R&D, commercialization spend, and hiring, and makes the company dependent on external funding or asset sales to sustain operations, raising execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / solid solvency
A very low debt load provides durable financial flexibility: it reduces near-term default and interest burden, supports the ability to raise growth capital on better terms, and gives time to execute R&D and commercialization plans without immediate solvency pressure.
Read all positive factors
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$569.60M
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)―
Beta (1Y)1.78
Revenue GrowthN/A
EPS Growth20.16%
CountryHK
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding235,703,410
10 Day Avg. Volume3,698,147
30 Day Avg. Volume2,141,365
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)2.91
Price to Sales (P/S)28.92
P/FCF Ratio-17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (B...
How the Company Makes Money
Publicly verifiable, company-specific details describing Shanghai Bio-Heart Biological Technology Co., Ltd.’s revenue model (e.g., disclosed primary revenue streams, named products generating sales, licensing terms, manufacturing/service income, o...
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
17
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 43.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -157.81K | 0.00 | -23.60M | -24.25M | 0.00 |
| EBITDA | -52.13M | -44.54M | -148.21M | -237.34M | -400.88M |
| Net Income | -68.24M | -87.94M | -194.36M | -237.50M | -361.45M |
Balance Sheet | |||||
| Total Assets | 832.83M | 733.78M | 817.90M | 981.52M | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 248.63M | 202.39M | 369.44M | 451.32M | 708.53M |
| Total Debt | 12.73M | 8.28M | 1.76M | 18.11M | 22.45M |
| Total Liabilities | 220.47M | 53.24M | 44.04M | 66.47M | 80.04M |
| Stockholders Equity | 435.00M | 660.47M | 748.41M | 883.21M | 995.69M |
Cash Flow | |||||
| Free Cash Flow | -72.91M | -166.69M | -66.74M | -170.65M | -147.28M |
| Operating Cash Flow | -65.48M | -119.55M | -49.03M | -140.62M | -105.45M |
| Investing Cash Flow | -39.78M | -46.03M | -28.86M | -100.69M | -33.73M |
| Financing Cash Flow | -1.74M | -2.44M | -5.82M | -35.18M | 383.68M |
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Technical Analysis
Negative
5.71
Price Trends
3.71
Negative
4.39
Negative
5.70
Negative
Market Momentum
-0.37
Positive
21.40
Positive
10.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2185, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 2.93, above the 50-day MA of 3.71, and above the 200-day MA of 5.70, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 21.40 is Positive, neither overbought nor oversold. The STOCH value of 10.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2185.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | HK$16.72B | 81.62 | 11.29% | ― | 40.78% | 410.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$9.49B | -76.78 | -11.21% | ― | 219.26% | 87.63% | |
49 Neutral | HK$1.57B | 24.05 | 43.89% | ― | 150.60% | ― | |
44 Neutral | HK$569.60M | -6.86 | -15.19% | ― | ― | 20.16% | |
43 Neutral | HK$775.40M | -7.13 | 485.24% | ― | -38.07% | 13.45% | |
41 Neutral | HK$970.43M | -10.16 | -16.53% | ― | ― | ― |
* Healthcare Sector Average
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
2.34
-1.36
-36.76%
HK:2171
CARsgen Therapeutics Holdings Ltd.
15.75
-7.75
-32.98%
HK:2181
Mabpharm Limited
0.38
-0.09
-19.15%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
40.94
21.04
105.73%
HK:2496
Wuhan YZY Biopharma Co., Ltd. Class H
4.00
-1.16
-22.48%
HK:2898
Sunho Biologics,Inc.
6.39
1.11
21.02%
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Bio-heart Wins Israel Registration for Iberis Renal Denervation System
Jun 9, 2026
Shanghai Bio-heart’s subsidiary AngioCare has secured registration in Israel for its Iberis Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System, expanding the global footprint of its renal denervation technology. The system,...
Shanghai Bio-heart Sets 2025 AGM to Vote on Governance Overhaul and Supervisory Board Abolition
Jun 1, 2026
Shanghai Bio-heart Biological Technology has called its 2025 annual general meeting for June 26, 2026 in Shanghai, where shareholders will review the 2025 board and supervisory reports, the audited consolidated financial statements, the annual rep...
Shanghai Bio-Heart Overhauls Governance Structure Ahead of 2026 AGM
May 26, 2026
Shanghai Bio-Heart Biological Technology Co., Ltd. plans to abolish its board of supervisors and replace its functions with an audit committee under the board of directors, in line with amendments to the PRC Company Law and updated regulatory guid...
Shanghai Bio-Heart Wins Vietnam Approval for Iberis Renal Denervation System
May 11, 2026
Shanghai Bio-Heart’s subsidiary AngioCare has secured registration of its Iberis multi-electrode renal artery radiofrequency ablation catheter system in Vietnam, expanding the device’s international footprint. The system, developed for...
Shanghai Bio-Heart Narrows Loss as Iberis RDN Launch Drives First Revenue
Mar 26, 2026
Shanghai Bio-Heart Biological Technology reported its first full year of revenue, booking RMB44.9 million in 2025 from the global launch of its Iberis RDN system for resistant hypertension, including the first commercial procedure in Europe and pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.